A study about the use of whole body cooling for severe respiratory distress due to meconium aspiration syndrome (MAS) in neonates

ISRCTN ISRCTN10541833
DOI https://doi.org/10.1186/ISRCTN10541833
Secondary identifying numbers 2.0
Submission date
21/11/2015
Registration date
24/11/2015
Last edited
04/11/2016
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Neonatal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Hypoxic-ischemic encephalopathy (HIE) is a brain injury caused by lack of oxygen. Cooling (called whole body hypothermia [WBH]) is the standard treatment for newborn babies affected by HIE occurring at delivery. HIE is often associated with meconium aspiration syndrome (MAS), a severe respiratory problem that often occurs in newborns together with HIE. MAS occurs when a newborn baby breathes a mixture of meconium and amniotic fluid into the lungs around the time of delivery. The aim of this study is to clarify the effect of WBH on oxygenation and respiratory outcomes in MAS.

Who can participate?
Newborn babies with MAS born during 2006-2014 who were treated or not treated with WBH for HIE .

What does the study involve?
The clinical outcomes of babies who were treated with WBH are compared with the clinical outcomes of babies who were not treated with WBH.

What are the possible benefits and risks of participating?
There are neither benefits nor risks for participants.

Where is the study run from?
Eleven neonatal or pediatric intensive care units in Europe, Australia, South and North America. The study is being coordinated at the South Paris University Hospitals (France).

When is the study starting and how long is it expected to run for?
January 2006 to November 2015

Who is funding the study?
Not provided at time of registration

Who is the main contact?
Prof. Daniele De Luca

Contact information

Prof Daniele De Luca
Scientific

Service de Reanimation Neonatale
GHU Paris Sud
Hopital "A.Beclere"
157 rue de la Porte de Trivaux
Clamart (Paris)
92140
France

Study information

Study designInternational multicentre retrospective cohort study (observational)
Primary study designObservational
Secondary study designCohort study
Study setting(s)Hospital
Study typeTreatment
Participant information sheet Not available in web format, please use the contact details to request a patient information sheet
Scientific titleWhole body hypothermia and meconium aspiration syndrome: international multicentre retrospective cohort study
Study acronymMASH (Meconium Aspiration Syndrome Hypothermia)
Study objectivesWhole body hypothermia might improve gas exchange and clinical outcomes in MAS patients, especially in those with more severe lung disease.
Ethics approval(s)Ethical Committee of the French Society for Critical Care (SRLF), 19/11/2015, ref: 15/08
Health condition(s) or problem(s) studiedMeconium aspiration syndrome
InterventionThe intervention being tested is whole body hypothermia. There are interesting animal and translational data suggesting the usefulness of whole body hypothermia for some forms of respiratory failure although this has never been studied on clinical grounds before. Conversely, hypothermia is already an established therapy for hypoxic ischemic encephalopathy (HIE).

The study cohort consisted of babies affected by MAS and treated with whole body hypothermia (WBH) according to TOBY trial criteria for HIE (‘cooled’ neonates). The control cohort consisted of MAS babies with or without a diagnosis of HIE, in whom TOBY criteria were not met and WBH was not started (‘uncooled’ neonates) .
Intervention typeProcedure/Surgery
Primary outcome measureGas exchange over the first 72 hours of life (as described by oxygenation index, PaCO2 and pH)
Secondary outcome measures1. Duration of invasive mechanical ventilation
2. Total duration of respiratory support (defined as the total time spent under invasive, non-invasive ventilation, continuous positive airway pressure/high flow nasal cannulae and free oxygen therapy)
3. Length of stay in the intensive care unit
4. Length of hospital stay
Overall study start date01/01/2006
Completion date01/11/2015

Eligibility

Participant type(s)Patient
Age groupNeonate
SexBoth
Target number of participantsPilot study (impossible to calculate given the lack of preliminary data on the topic)
Key inclusion criteriaStudy cohort consisted of MAS neonates treated with WBH according to the TOBY trial criteria (see above).
Control cohort consisted of MAS babies in whom TOBY criteria were not met and WBH was not instigated.

All babies had to fulfill the following MAS diagnostic criteria:
1. Meconium-stained amniotic fluid
2. Need for intubation and tracheal suctioning in the delivery room according to the American Academy of Pediatrics neonatal resuscitation guidelines
3. Typical chest radiograph appearance
4. Oxygenation index (OI) > 10 at the intensive care unit admission
Key exclusion criteria1. Major congenital malformation or known chromosomal abnormalities
2. Any lung disease other than MAS
3. Need for extra-corporeal membrane oxygenation (ECMO)
Date of first enrolment01/01/2006
Date of final enrolment31/12/2014

Locations

Countries of recruitment

  • Australia
  • Brazil
  • England
  • France
  • Italy
  • Netherlands
  • Spain
  • United Kingdom
  • United States of America

Study participating centres

South Paris University Hospitals
Medical Center "A. Beclere"
Division of Pediatrics and Neonatal Critical Care
92140
France
Università Cattolica del Sacro Cuore
Policlinico Universitario "A. Gemelli"
TIN e TIP
00168
Italy
Murdoch Childrens Research Institute
Neonatology
Royal Children’s Hospital
Department of Paediatrics
University of Melbourne
VIC 3052
Australia
Academic Medical Center
Amsterdam
1105 AZ
Netherlands
NICU Hospital "La Paz"
Universidad Autonoma de Madrid
28029
Spain
John Radcliffe Hospital
Oxford University Hospitals NHS Trust
OX39DU
United Kingdom
University Hospital of University of São Paulo
Department of Pediatrics
2565
Brazil
San Francisco General Hospital
UCSF University of California
CA 94110
United States of America
Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
Department of Clinical Sciences and Community Health
Università degli Studi di Milano
20122
Italy
Women’s and Children Hospital "G. Salesi"
Polytechnical University of Marche
60123
Italy
University of Sheffield
S10 2TN
United Kingdom

Sponsor information

Individual sponsor (Italy)
Other

Prof. Marco Piastra
Terapia Intensiva Pediatrica (DEA)
Policlinico Univ."A. Gemelli"
Università Cattolica del Sacro Cuore
L.go A.Gemelli 8
Rome
00168
Italy

Funders

Funder type

Other

Investigator initiated and funded

No information available

Results and Publications

Intention to publish date
Individual participant data (IPD) Intention to shareNo
IPD sharing plan summaryStored in repository
Publication and dissemination planStudy results have been or will be (at least partially) presented at the main European meetings (ESPNIC 2015 and ESPR/jENS 2015) and at the Pediatric Academic Societies Meeting in the US (PAS/SPR 2015). During 2015/2016 a full paper should be sent for publication in a major international journal.
IPD sharing plan

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Results article results 01/08/2016 Yes No

Editorial Notes

04/11/2016: Publication reference added.